These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2185353)

  • 1. The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of albumin.
    Dunn MJ
    J Hypertens Suppl; 1990 Mar; 8(1):S47-51; discussion S51-2. PubMed ID: 2185353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
    Packer M
    Circulation; 1988 Jun; 77(6 Pt 2):I64-73. PubMed ID: 2967129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glomerular prostaglandins, angiotensin II, and nonsteroidal anti-inflammatory drugs.
    Scharschmidt L; Simonson M; Dunn MJ
    Am J Med; 1986 Aug; 81(2B):30-42. PubMed ID: 3092664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility.
    Remuzzi A; Remuzzi G
    Semin Nephrol; 1995 May; 15(3):236-43. PubMed ID: 7631050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies.
    Hilgers KF; Mann JF
    Kidney Blood Press Res; 1996; 19(5):254-62. PubMed ID: 8956237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
    Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
    Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.
    Heeg JE; de Jong PE; de Zeeuw D
    Clin Sci (Lond); 1991 Sep; 81(3):367-72. PubMed ID: 1655338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions.
    Dunn M
    Drugs; 1987; 33 Suppl 1():56-66. PubMed ID: 3109872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F
    BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of the nephrotoxicity of non-steroidal anti-inflammatory drugs.
    Dunn MJ; Scharschmidt L; Zambraski E
    Arch Toxicol Suppl; 1984; 7():328-37. PubMed ID: 6595999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal prostaglandin synthesis and angiotensin-converting enzyme inhibition.
    Wilson TW
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S39-44. PubMed ID: 1382164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.
    Toto RD; Adams-Huet B; Fenves AZ; Mitchell HC; Mulcahy W; Smith RD
    Am J Kidney Dis; 1996 Dec; 28(6):832-40. PubMed ID: 8957034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.
    Heeg JE; de Jong PE; van der Hem GK; de Zeeuw D
    Kidney Int; 1991 Oct; 40(4):734-41. PubMed ID: 1660550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal regulation of glomerular filtration.
    Kon V; Ichikawa I
    Annu Rev Med; 1985; 36():515-31. PubMed ID: 2986529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease.
    Remuzzi A; Mohamed EI
    Exp Nephrol; 1996; 4 Suppl 1():27-33. PubMed ID: 9001894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension.
    Rugale C; Cordaillat M; Mimran A; Jover B
    J Renin Angiotensin Aldosterone Syst; 2005 Dec; 6(3):154-60. PubMed ID: 16525947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.
    Schieppati A; Remuzzi G
    Kidney Int; 2003 Dec; 64(6):1947-55. PubMed ID: 14633117
    [No Abstract]   [Full Text] [Related]  

  • 19. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X; Matavelli LC; Ono H; Frohlich ED
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome.
    Remuzzi A; Schieppati A; Battaglia C; Remuzzi G
    Am J Kidney Dis; 1989 Sep; 14(3):170-7. PubMed ID: 2476029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.